Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ
Real-time Data
01:30 PM
Day's Range
734.1852 wk Range
541.00Overview - REGN - Regeneron Pharmaceuticals, Inc.
Key Statistics
Valuation
Enterprise Value
73.40B
P/E (Trailing)
‪19.49‬
P/E (Forward)
‪12.94‬
PEG Ratio
‪-4.16‬
Price / Sales (TTM)
‪5.22‬
Price / Book
‪2.49‬
EV / EBITDA
‪15.60‬
Profitability
Gross Margin
‪86.56%‬
Profit Margin
‪27.86%‬
Operating Margin
‪33.10%‬
Return on Assets
‪6.52%‬
Return on Equity
‪14.04%‬
Ownership
Shares Outstanding
103.13M
Float
95.84M
Short % of Shares Outstanding
‪2.59%‬
Held by Insiders
‪2.08%‬
Held by Institutions
‪93.53%‬
Price stats
Beta
‪0.19‬
50-Day Avg
‪774.60‬
200-Day Avg
‪735.26‬
Dividends
Payout Ratio
‪9.01%‬
Frequency
Quarterly
Analyst Consensus
27 analysts
Average price target
‪$ 840.43‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - REGN - Regeneron Pharmaceuticals, Inc.
Peers - REGN - Regeneron Pharmaceuticals, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- REGNNASDAQRegeneron Pharmaceuticals, Inc.81.13BMarket Cap+28.84%52-week change19.49P/E (Trailing)‪27.86%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - REGN - Regeneron Pharmaceuticals, Inc.
About
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for people with serious diseases. Its portfolio spans treatments in eye care, immunology, oncology, cardiovascular and metabolic disease, infectious disease, hematology, and rare disorders.…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
